EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6
04/11/2024 07:50
BRUSSELS, Nov 4 (Reuters) - EU antitrust regulators will
decide by Dec. 6 whether to clear Novo Holdings' acquisition of
contract drug manufacturer Catalent CTLT.N , according to a
filing on the European Commission website on Monday.
The controlling shareholder of Novo Nordisk NOVOb.CO put
in a request for EU approval for the deal on Oct. 31, the filing
showed.
The EU antitrust can either clear the deal with or without
remedies or it can open a full-scale four-month long
investigation if it has serious concerns.
(Reporting by Foo Yun Chee)
((foo.yunchee@thomsonreuters.com; +32 2 585 2866; Reuters
Messaging: foo.yunchee.thomsonreuters.com@reuters.net))
Recent news on Catalent
See all newsBrief: Novo Holdings Completes Acquisition Of Catalent
Novo Nordisk rises as Catalent deal in US nears
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
Brief: Catalent And Novo Holdings Fulfill All Regulatory Closing Conditions For Pending Transaction
Brief: Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled